Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma

Area of Science:

• Dermatology
• Rheumatology
• Internal Medicine

Background:

• Panniculitis is an uncommon skin manifestation associated with connective tissue diseases.
• It can occur in the context of lupus erythematosus, dermatomyositis, and scleroderma/morphea.
• These conditions share an active inflammatory phase that may lead to scarring, atrophy, and calcification.

Purpose of the Study:

• To discuss panniculitis as a manifestation of lupus erythematosus, dermatomyositis, and scleroderma/morphea.
• To highlight the common inflammatory progression and potential sequelae of these panniculitis subtypes.
• To outline treatment strategies for panniculitis in the setting of these connective tissue diseases.

Main Methods:

• Review of literature on panniculitis associated with lupus erythematosus, dermatomyositis, and scleroderma/morphea.
• Discussion of the clinical presentation, histopathology, and disease progression.
• Analysis of treatment approaches based on the underlying connective tissue disease.

Main Results:

• Panniculitis subtypes share an active inflammatory stage with potential for scarring, atrophy, and calcification.
• Early intervention during the active phase is crucial for effective management.
• Treatment efficacy is often dependent on systemic therapy due to inflammation location.

Conclusions:

• Panniculitis in connective tissue diseases necessitates prompt and often systemic treatment.
• Antimalarials are recommended for lupus erythematosus panniculitis.
• Corticosteroids combined with immunosuppressive agents are first-line for dermatomyositis panniculitis, while morphea/scleroderma panniculitis treatment is guided by severity.